EP1836201B2 - Pyrrolidine als inhibitoren von iap - Google Patents

Pyrrolidine als inhibitoren von iap Download PDF

Info

Publication number
EP1836201B2
EP1836201B2 EP05854815.7A EP05854815A EP1836201B2 EP 1836201 B2 EP1836201 B2 EP 1836201B2 EP 05854815 A EP05854815 A EP 05854815A EP 1836201 B2 EP1836201 B2 EP 1836201B2
Authority
EP
European Patent Office
Prior art keywords
mmol
mixture
alkyl
ref
afford
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
EP05854815.7A
Other languages
English (en)
French (fr)
Other versions
EP1836201B1 (de
EP1836201A1 (de
Inventor
Frederick Cohen
John A. Flygare
Cuong Ly
Vickie Hsiao-Wei Tsui
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36129810&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP1836201(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of EP1836201A1 publication Critical patent/EP1836201A1/de
Publication of EP1836201B1 publication Critical patent/EP1836201B1/de
Application granted granted Critical
Publication of EP1836201B2 publication Critical patent/EP1836201B2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Claims (9)

  1. Verbindung, ausgewählt aus Verbindungen der Formel I sowie Salzen und Solvaten davon:
    Figure imgb0341
     worin:
    Ring A und Q zusammen eine Gruppe der Formel IIg sind:
    Figure imgb0342
    Q = H, Alkyl, ein Carbozyklus oder ein Heterozyklus ist; worin eine oder mehrere CH2- oder CH-Gruppen eines Alkyls gegebenenfalls durch -O-, -S-, -S(O)-, -S(O)2-, -N(R8)-, -C(O)-, -C(O)-NR8-, -NR8-C(O)-, -SO2-NR8-, -NR8-SO2-, -NR8-C(O)-NR8-, -NR8-C(NH)-NR8-, -NR8-C(NH)-, -C(O)-O- oder -O-C(O)- ersetzt sind; und ein Alkyl, Carbozyklus oder Heterozyklus gegebenenfalls mit einer oder mehreren aus Hydroxyl, Alkoxy, Acyl, Halogen, Mercapto, Carboxyl, halogensubstituiertem Alkyl, Amino, Cyano, Nitro, Amidino, Guanidino, einem gegebenenfalls substituiertem Carbozyklus und einem gegebenenfalls substituierten Heterozyklus substituiert ist, worin die optionalen Substituenten des "gegebenenfalls substituierten Carbozyklus" und des "gegebenenfalls substituierten Heterozyklus" Hydroxyl, Alkyl, Alkoxy, Acyl, Halogen, Mercapto, Carboxyl, halogensubstituiertes Alkyl, Amino, Cyano, Nitro, Amidino und Guanidino sind;
    X1 und X2 beide O sind;
    Y = CH2 ist;
    R1 = H ist;
    R2 t-Butyl, Isopropyl, Cyclohexyl, Cyclopentyl, Phenyl oder Tetrahydropyran-4-yl ist;
    R3 = H, Methyl, Ethyl, Propyl oder Isopropyl ist;
    R3' = H ist;
    R4 = H oder Methyl ist;
    R4' = H ist;
    R5 = H oder Methyl ist;
    R6 und R6' jeweils unabhängig voneinander H oder Methyl sind;
    R7 = H ist; und
    R8 = H, Methyl oder Acetyl ist.
  2. Verbindung nach Anspruch 1, worin Q ein Carbozyklus oder Heterozyklus ist, der gegebenenfalls mit Halogen, Amino, Alkyl, einem Carbozyklus oder einem Heterozyklus substituiert ist; worin eine oder mehrere CH2- oder CH-Gruppen eines Alkyls gegebenenfalls durch -O-, -S-, -S(O)-, -S(O)2-, -N(R8)-, -C(O)-, -C(O)-NR8-, -NR8-C(O)-, -SO2-NR8-, -NR8-SO2-, -NR8-C(O)-NR8-, -NR8-C(NH)-NR8-, -NR8-C(NH)-, -C(O)-O- oder -O-C(O)- ersetzt sind; und worin das Alkyl, der Carbozyklus oder der Heterozyklus gegebenenfalls mit Halogen, Amino, Hydroxyl, Mercapto, Carboxyl, Alkoxy, Alkoxyalkoxy, Hydroxyalkoxy, Alkylthio, Acyloxy, Acyloxyalkoxy, Alkylsulfonyl, Alkylsulfonylalkyl, Alkylsulfinyl und Alkylsulfinylalkyl substituiert ist.
  3. Verbindung nach Anspruch 1, worin Q aus Gruppen der Formeln IIIa bis IIIi ausgewählt ist:
    Figure imgb0343
    Figure imgb0344
    Figure imgb0345
     worin:
    n = 1 bis 4 ist;
    T = O, S, NR8 oder CR7R7 ist;
    W = O, NR8 oder CR7R7 ist;
    R7 = H, F, Cl, Me, Methoxy, Hydroxyethoxy, Methoxyethoxy, Acetoxymethoxy, Methylsulfonyl, Methylsulfonylmethyl, Phenyl oder Morpholin-4-yl ist; und
    R8 = H ist.
  4. Verbindung nach einem der Ansprüche 1 bis 3, worin R3 Methyl ist.
  5. Verbindung nach einem der Ansprüche 1 bis 4 zur Verwendung in einem Verfahren zur Behandlung eines menschlichen oder tierischen Körpers mittels Therapie.
  6. Verbindung zur Verwendung nach Anspruch 5 in einem Verfahren zur Behandlung einer Erkrankung oder eines Leidens im Zusammenhang mit der Überexpression eines Apoptoseinhibitors (IAP) bei einem Säugetier.
  7. Verbindung zur Verwendung nach Anspruch 5 in einem Verfahren zur Behandlung von Krebs.
  8. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 4 bei der Herstellung eines Medikaments zur Behandlung einer Erkrankung oder eines Leidens im Zusammenhang mit der Überexpression eines Apoptoseinhibitors (IAP) bei einem Säugetier.
  9. Verwendung einer Verbindung nach einem der Ansprüche 1 bis 4 bei der Herstellung eines Medikaments zur Behandlung von Krebs.
EP05854815.7A 2004-12-20 2005-12-19 Pyrrolidine als inhibitoren von iap Active EP1836201B2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63820204P 2004-12-20 2004-12-20
PCT/US2005/046161 WO2006069063A1 (en) 2004-12-20 2005-12-19 Pyrrolidine inhibitors of iap

Publications (3)

Publication Number Publication Date
EP1836201A1 EP1836201A1 (de) 2007-09-26
EP1836201B1 EP1836201B1 (de) 2010-08-11
EP1836201B2 true EP1836201B2 (de) 2013-09-04

Family

ID=36129810

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05854815.7A Active EP1836201B2 (de) 2004-12-20 2005-12-19 Pyrrolidine als inhibitoren von iap

Country Status (19)

Country Link
US (4) US20060167066A1 (de)
EP (1) EP1836201B2 (de)
JP (2) JP5007235B2 (de)
KR (2) KR20120127754A (de)
CN (1) CN101146803A (de)
AT (1) ATE477254T1 (de)
AU (1) AU2005319305B2 (de)
CA (1) CA2588921C (de)
DE (1) DE602005022936D1 (de)
DK (1) DK1836201T4 (de)
EA (1) EA019420B1 (de)
ES (1) ES2349110T5 (de)
HK (1) HK1109155A1 (de)
IL (1) IL183514A (de)
MX (1) MX2007007195A (de)
NO (1) NO339157B1 (de)
NZ (1) NZ589670A (de)
WO (1) WO2006069063A1 (de)
ZA (1) ZA200704910B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Families Citing this family (119)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002102820A1 (en) 2001-06-20 2002-12-27 Nuevolution A/S Nucleoside derivatives for library preparation
IL163822A0 (en) 2002-03-15 2005-12-18 Nuevolution As An improved method for synthesising templated molecules
WO2004013070A2 (en) 2002-08-01 2004-02-12 Nuevolution A/S Multi-step synthesis of templated molecules
PT1558744E (pt) 2002-10-30 2011-09-22 Nuevolution As Codificação enzimática
ATE450609T1 (de) 2002-12-19 2009-12-15 Nuevolution As Durch quasizufallsstrukturen und funktionen geführte synthesemethode
EP1597395A2 (de) 2003-02-21 2005-11-23 Nuevolution A/S Methode zur herstellung einer bibliothek der zweiten generation
EP1670939B1 (de) 2003-09-18 2009-11-04 Nuevolution A/S Methode zur Gewinnung struktureller Informationen kodierter Moleküle und zur Selektion von Verbindungen
JP4691549B2 (ja) 2004-04-07 2011-06-01 ノバルティス アーゲー Ｉａｐの阻害剤
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
CA2598995C (en) 2005-02-25 2014-07-15 Stephen M. Condon Dimeric iap inhibitors
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
EP1907384A2 (de) * 2005-06-30 2008-04-09 Prosidion Limited Gpcr-agonisten
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
DE102005046907A1 (de) 2005-09-30 2007-04-12 Voith Patent Gmbh Verfahren und Vorrichtung zur Herstellung einer Tissuebahn
BRPI0617751A2 (pt) 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
DE602006018648D1 (de) 2005-12-01 2011-01-13 Nuevolution As Enzymvermittelnde kodierungsmethoden für eine effiziente synthese von grossen bibliotheken
CA2632807A1 (en) * 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
CN101535300B (zh) 2006-05-16 2014-05-28 埃格拉医疗公司 Iap bir域结合化合物
WO2008014236A1 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
EP2049524A2 (de) * 2006-07-24 2009-04-22 Tetralogic Pharmaceuticals Corporation Iap-hemmer
US20100113326A1 (en) * 2006-07-24 2010-05-06 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100144650A1 (en) * 2006-07-24 2010-06-10 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US7985735B2 (en) * 2006-07-24 2011-07-26 Tetralogic Pharmaceuticals Corporation Dimeric IAP inhibitors
PE20110224A1 (es) 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
EP2102229B1 (de) * 2006-10-12 2014-03-26 Novartis AG Pyrrolydinderivate als iap-inhibitoren
AU2007337104A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of IAP
MX2009010667A (es) 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
MX2009011783A (es) * 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
JP2010528587A (ja) * 2007-05-07 2010-08-26 テトラロジック ファーマシューティカルズ コーポレーション アポトーシス阻害タンパク質のアンタゴニストに対する感受性のバイオマーカーとしてＴＮＦα遺伝子の発現を用いる方法
JP5176452B2 (ja) * 2007-09-27 2013-04-03 住友化学株式会社 光学活性なテトラヒドロピラニルグリシン化合物の製造方法
WO2009089502A1 (en) * 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of iap
US9029411B2 (en) 2008-01-25 2015-05-12 Millennium Pharmaceuticals, Inc. Thiophenes and uses thereof
TW201011006A (en) * 2008-06-16 2010-03-16 Nuevolution As IAP binding compounds
JP2011529962A (ja) 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
CA2730357A1 (en) * 2008-08-16 2010-02-25 Genetech, Inc. Azaindole inhibitors of iap
CN102395585A (zh) * 2009-01-30 2012-03-28 米伦纽姆医药公司 杂芳基化合物和其作为pi3k抑制剂的用途
US9090601B2 (en) 2009-01-30 2015-07-28 Millennium Pharmaceuticals, Inc. Thiazole derivatives
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
WO2011016576A1 (en) 2009-08-04 2011-02-10 Takeda Pharmaceutical Company Limited Alanine derivatives as inhibitors of apoptosis proteins
SG177713A1 (en) * 2009-08-12 2012-02-28 Novartis Ag Solid oral formulations and crystalline forms of an inhibitor of apoptosis protein
US20120196793A1 (en) 2009-09-18 2012-08-02 Firestone Brant G Biomarkers for iap inhibitor compounds
EP2784076A1 (de) 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimere SMAC-Mimetika
MY159958A (en) * 2009-12-18 2017-02-15 Idenix Pharmaceuticals Inc 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
WO2011098904A1 (en) 2010-02-12 2011-08-18 Aegera Therapeutics, Inc. Iap bir domain binding compounds
ES2713873T3 (es) 2010-04-16 2019-05-24 Nuevolution As Complejos bifuncionales y métodos para hacer y utilizar tales complejos
US9062038B2 (en) 2010-08-11 2015-06-23 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP2688864A1 (de) 2011-03-22 2014-01-29 Syngenta Participations AG Insektizidverbindungen
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
CN102757426A (zh) * 2011-04-28 2012-10-31 中国医学科学院医药生物技术研究所 一种苯并异恶唑基取代的噻唑类化合物、制备方法及用途
NO2755614T3 (de) * 2012-01-03 2018-03-31
KR102204989B1 (ko) 2012-01-12 2021-01-20 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
AU2013256182A1 (en) 2012-05-04 2014-11-13 Novartis Ag Biomarkers for IAP inhibitor therapy
GB201218850D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
US9980973B2 (en) 2012-10-19 2018-05-29 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
GB201218862D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
GB201218864D0 (en) 2012-10-19 2012-12-05 Astex Therapeutics Ltd Bicyclic heterocycle compounds and their uses in therapy
DK2963125T3 (da) * 2013-02-15 2020-10-12 Univ Nat Corp Tokyo Medical & Dental Terapeutisk middel til behandling af en cancer, hvor NRF2 er stabiliseret
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MA38396B1 (fr) 2013-03-15 2019-05-31 Novartis Ag Anticorps medicamenteux conjugues et leurs compositions pharmaceutiques pour traiter un cancer positif a ckit
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
CN105829310B (zh) 2013-12-20 2019-04-12 阿斯特克斯治疗有限公司 双环杂环化合物及其治疗用途
CA2950911C (en) 2014-06-04 2023-10-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
WO2016020791A1 (en) 2014-08-05 2016-02-11 Novartis Ag Ckit antibody drug conjugates
US10071164B2 (en) 2014-08-11 2018-09-11 Yale University Estrogen-related receptor alpha based protac compounds and associated methods of use
WO2016024195A1 (en) 2014-08-12 2016-02-18 Novartis Ag Anti-cdh6 antibody drug conjugates
KR20230119040A (ko) 2015-01-20 2023-08-14 아비나스 오퍼레이션스, 인코포레이티드 안드로겐 수용체의 표적화된 분해를 위한 화합물 및방법
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US20190194315A1 (en) 2015-06-17 2019-06-27 Novartis Ag Antibody drug conjugates
WO2017030814A1 (en) 2015-08-19 2017-02-23 Arvinas, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
MA44334A (fr) 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
MX2019005007A (es) 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
KR102173464B1 (ko) 2016-12-01 2020-11-04 아비나스 오퍼레이션스, 인코포레이티드 에스트로겐 수용체 분해제로서의 테트라히드로나프탈렌 및 테트라히드로이소퀴놀린 유도체
EP3559006A4 (de) 2016-12-23 2021-03-03 Arvinas Operations, Inc. Verbindungen und verfahren zum gezielten abbau von fetalen leberkinasepolypeptiden
KR102564201B1 (ko) 2016-12-23 2023-08-07 아비나스 오퍼레이션스, 인코포레이티드 급속 진행성 섬유육종 폴리펩티드의 표적화 분해를 위한 화합물 및 방법
EP3559002A4 (de) 2016-12-23 2021-02-17 Arvinas Operations, Inc. Auf egfr-proteolyse gerichtete chimäre moleküle und zugehörige verfahren zur verwendung
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
EP3573977A4 (de) 2017-01-26 2020-12-23 Arvinas Operations, Inc. Modulatoren der östrogenrezeptorproteolyse und zugehörige verfahren zur verwendung
JOP20190187A1 (ar) 2017-02-03 2019-08-01 Novartis Ag مترافقات عقار جسم مضاد لـ ccr7
EP3592868B1 (de) 2017-03-06 2022-11-23 Novartis AG Verfahren zur behandlung von krebs mit reduzierter ubb-expression
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
WO2018215937A1 (en) 2017-05-24 2018-11-29 Novartis Ag Interleukin-7 antibody cytokine engrafted proteins and methods of use in the treatment of cancer
EP3630162A1 (de) 2017-05-24 2020-04-08 Novartis AG Antikörper-zytokin-gepfropfte proteine und verfahren zur verwendung
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
KR20200031127A (ko) * 2017-07-25 2020-03-23 헤파진 테라퓨틱스, 인크. 세포자멸사 단백질의 이량체 펩타이드 억제제
PL3712162T3 (pl) * 2017-11-13 2022-11-14 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. MIMETYKI SMAC STOSOWANE JAKO INHIBITORY lAP I ICH ZASTOSOWANIE
EP3710443A1 (de) 2017-11-17 2020-09-23 Arvinas Operations, Inc. Verbindungen und verfahren zum gezielten abbau von mit interleukin-1-rezeptor assoziierten kinase-4-polypeptiden
TWI812673B (zh) 2018-02-12 2023-08-21 美商富曼西公司 用於防治無脊椎害蟲之萘異噁唑啉化合物
CA3095494C (en) 2018-04-04 2023-11-07 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
SG11202011872QA (en) 2018-07-10 2021-01-28 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
US20200038513A1 (en) 2018-07-26 2020-02-06 Arvinas Operations, Inc. Modulators of fak proteolysis and associated methods of use
WO2020041331A1 (en) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Proteolysis targeting chimeric (protac) compound with e3 ubiquitin ligase binding activity and targeting alpha-synuclein protein for treating neurodegenerative diseases
JP2022500368A (ja) 2018-09-07 2022-01-04 アルビナス・オペレーションズ・インコーポレイテッドArvinas Operations, Inc. 急速進行性線維肉腫ポリペプチドの標的分解のための多環式化合物および方法
EP3873532A1 (de) 2018-10-31 2021-09-08 Novartis AG Dc-sign-antikörper-arzneimittelkonjugate
JP2022514315A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体を含む投与計画及び薬剤組み合わせ
JP2022515760A (ja) 2018-12-21 2022-02-22 ノバルティス アーゲー Ｐｍｅｌ１７に対する抗体及びその結合体
KR20210129672A (ko) 2019-02-15 2021-10-28 노파르티스 아게 치환된 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체 및 이의 용도
CA3124935A1 (en) 2019-02-15 2020-08-20 Novartis Ag 3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20220185815A1 (en) 2019-03-06 2022-06-16 Daiichi Sankyo Company, Limited Pyrrolopyrazole derivative
AU2020274768A1 (en) * 2019-05-10 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline form of smac mimic used as iap inhibitor and preparation method thereof
US11912699B2 (en) 2019-07-17 2024-02-27 Arvinas Operations, Inc. Tau-protein targeting compounds and associated
EP4007592A1 (de) 2019-08-02 2022-06-08 LanthioPep B.V. Rezeptoragonisten von angiotensin typ 2 (at2) zur behandlung von krebs
CN115052662A (zh) 2019-12-20 2022-09-13 诺华股份有限公司 抗TGFβ抗体和检查点抑制剂用于治疗增殖性疾病的用途
US20230181756A1 (en) 2020-04-30 2023-06-15 Novartis Ag Ccr7 antibody drug conjugates for treating cancer
JP2023529211A (ja) 2020-06-11 2023-07-07 ノバルティス アーゲー Ｚｂｔｂ３２阻害剤及びその使用
JP2023531676A (ja) 2020-06-23 2023-07-25 ノバルティス アーゲー ３－（１－オキソイソインドリン－２－イル）ピぺリジン－２，６－ジオン誘導体を含む投与レジメン
CN116134027A (zh) 2020-08-03 2023-05-16 诺华股份有限公司 杂芳基取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
WO2022221720A1 (en) 2021-04-16 2022-10-20 Novartis Ag Antibody drug conjugates and methods for making thereof
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
WO2023214325A1 (en) 2022-05-05 2023-11-09 Novartis Ag Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
WO2024023666A1 (en) 2022-07-26 2024-02-01 Novartis Ag Crystalline forms of an akr1c3 dependent kars inhibitor
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE430062B (sv) 1977-03-04 1983-10-17 Pharmacia Fine Chemicals Ab Kopplings- eller tioleringsreagens
DE2714880A1 (de) * 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
FR2575753B1 (fr) * 1985-01-07 1987-02-20 Adir Nouveaux derives peptidiques a structure polycyclique azotee, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP0217634B1 (de) * 1985-09-26 1992-06-10 Beckman Research Institute of the City of Hope Sequenzierung von Peptiden
US4935494A (en) * 1988-11-15 1990-06-19 City Of Hope C-terminal peptide and protein sequencing
CA2012306A1 (en) 1989-03-28 1990-09-28 Werner Neidhart Amino acid derivatives
DK167813B1 (da) * 1989-12-07 1993-12-20 Carlbiotech Ltd As Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat
WO1992001938A1 (en) 1990-07-20 1992-02-06 City Of Hope Derivatization of c-terminal proline
EP0752248B1 (de) 1992-11-13 2000-09-27 Idec Pharmaceuticals Corporation Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
US5559209A (en) * 1993-02-18 1996-09-24 The General Hospital Corporation Regulator regions of G proteins
KR19990067184A (ko) * 1995-10-30 1999-08-16 스튜어트 알. 수터, 스티븐 베네티아너, 피터 존 기딩스 프로테아제 억제제
AU7127298A (en) 1997-04-14 1998-11-11 Emory University Serine protease inhibitors
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6472172B1 (en) * 1998-07-31 2002-10-29 Schering Aktiengesellschaft DNA encoding a novel human inhibitor-of-apoptosis protein
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
CA2420534A1 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) * 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
AU2002253908A1 (en) 2001-02-08 2003-02-17 Thomas Jefferson University A conserved xiap-interaction motif in caspase-9 and smac/diablo for mediating apoptosis
EP1373263B1 (de) 2001-04-05 2004-10-27 Torrent Pharmaceuticals Ltd Heterocyclische verbindungen für alterungs und diabetes bedingte vasculare erkrankungen
CA2449168A1 (en) 2001-05-31 2002-12-05 The Trustees Of Princeton University Iap binding peptides and assays for identifying compounds that bind iap
WO2003040172A2 (en) * 2001-11-09 2003-05-15 Aegera Therapeutics, Inc. Methods and reagents for peptide-bir interaction screens
WO2003086470A2 (en) 2002-04-17 2003-10-23 Deutsches Krebsforschungszentrum Smac-peptides as therapeutics against cancer and autoimmune diseases
CA2491041A1 (en) * 2002-07-02 2004-01-15 Novartis Ag Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) * 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
WO2004017991A1 (en) 2002-08-13 2004-03-04 Cell Center Cologne Gmbh Use of iap for the diagnosis and of iap-inhibitors for the treatment of hodgkin’s lymphomas
US20040171554A1 (en) * 2003-02-07 2004-09-02 Genentech, Inc. Compositions and methods for enhancing apoptosis
DE60322120D1 (de) 2003-02-07 2008-08-21 Genentech Inc Zusammensetzungen und verfahren für verstärkte apoptose
IL156263A0 (en) 2003-06-02 2004-01-04 Hadasit Med Res Service Livin-derived peptides, compositions and uses thereof
US7067274B2 (en) * 2003-11-13 2006-06-27 Genentech, Inc. Compositions and methods for the screening pro-apoptotic compounds
JP2007522116A (ja) 2004-01-16 2007-08-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン コンホメーションが制約されたＳｍａｃ模倣物およびその使用
JP2007523061A (ja) * 2004-01-16 2007-08-16 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Ｓｍａｃペプチドミメティクスおよびその使用法
JP4674231B2 (ja) 2004-03-01 2011-04-20 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム ２量体小分子アポトーシス増強剤
EP1740173A4 (de) 2004-03-23 2009-05-27 Genentech Inc Azabicyclooctan iap-inhibitoren
JP4691549B2 (ja) * 2004-04-07 2011-06-01 ノバルティス アーゲー Ｉａｐの阻害剤
KR100984459B1 (ko) 2004-07-02 2010-09-29 제넨테크, 인크. Ｉａｐ의 억제제
WO2006017295A2 (en) 2004-07-12 2006-02-16 Idun Pharmaceuticals, Inc. Tetrapeptide analogs
CA2574040C (en) 2004-07-15 2014-05-06 Tetralogic Pharmaceuticals Corporation Iap binding compounds
ATE477254T1 (de) 2004-12-20 2010-08-15 Genentech Inc Pyrrolidine als inhibitoren von iap
CA2598995C (en) * 2005-02-25 2014-07-15 Stephen M. Condon Dimeric iap inhibitors
JP4954983B2 (ja) 2005-05-18 2012-06-20 ファーマサイエンス・インコーポレイテッド Ｂｉｒドメイン結合化合物
BRPI0617751A2 (pt) * 2005-10-25 2011-08-02 Aegera Therapeutics Inc compostos de ligação do domìnio iap bir
CA2632807A1 (en) 2005-12-19 2007-09-20 Genentech, Inc. Inhibitors of iap
US7205737B1 (en) 2006-01-04 2007-04-17 Robert Bosch Gmbh Systems and methods of monitoring a motor load
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
EP1996184A4 (de) 2006-03-21 2010-09-22 Joyant Pharmaceuticals Inc Kleinmolekülige apoptose-promotoren
CN101490100B (zh) 2006-04-07 2012-08-22 派奥特雷克株式会社 交联的硝基氧聚合物的制备方法
WO2008014238A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
PE20110224A1 (es) 2006-08-02 2011-04-05 Novartis Ag PROCEDIMIENTO PARA LA SINTESIS DE UN PEPTIDOMIMETICO DE Smac INHIBIDOR DE IAP, Y COMPUESTOS INTERMEDIARIOS PARA LA SINTESIS DEL MISMO
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2102229B1 (de) 2006-10-12 2014-03-26 Novartis AG Pyrrolydinderivate als iap-inhibitoren
AU2007337104A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of IAP
MX2009011783A (es) 2007-04-30 2009-12-04 Genentech Inc Inhibidores de iap.
WO2009089502A1 (en) * 2008-01-11 2009-07-16 Genentech, Inc. Inhibitors of iap
JP2011529962A (ja) * 2008-08-02 2011-12-15 ジェネンテック， インコーポレイテッド Ｉａｐのインヒビター
CA2730357A1 (en) * 2008-08-16 2010-02-25 Genetech, Inc. Azaindole inhibitors of iap

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021220178A1 (en) 2020-04-29 2021-11-04 Cominnex Zrt. Iap antagonists and their therapeutic applications

Also Published As

Publication number Publication date
KR101278732B1 (ko) 2013-07-09
US20140080805A1 (en) 2014-03-20
KR20070089174A (ko) 2007-08-30
IL183514A0 (en) 2007-09-20
DK1836201T4 (da) 2013-11-11
CN101146803A (zh) 2008-03-19
US8609845B2 (en) 2013-12-17
US20090176822A1 (en) 2009-07-09
CA2588921A1 (en) 2006-06-29
NO20073783L (no) 2007-09-19
WO2006069063A1 (en) 2006-06-29
EA200701467A1 (ru) 2007-12-28
EP1836201B1 (de) 2010-08-11
CA2588921C (en) 2015-10-20
DK1836201T3 (da) 2010-12-06
US20060167066A1 (en) 2006-07-27
AU2005319305B2 (en) 2012-08-23
US9040706B2 (en) 2015-05-26
NZ589670A (en) 2013-01-25
DE602005022936D1 (de) 2010-09-23
NO339157B1 (no) 2016-11-14
ES2349110T3 (es) 2010-12-28
AU2005319305A1 (en) 2006-06-29
MX2007007195A (es) 2007-10-08
EA019420B1 (ru) 2014-03-31
EP1836201A1 (de) 2007-09-26
ZA200704910B (en) 2008-09-25
ES2349110T5 (es) 2013-11-27
JP2012184230A (ja) 2012-09-27
JP5007235B2 (ja) 2012-08-22
US20090318409A1 (en) 2009-12-24
JP2008524333A (ja) 2008-07-10
HK1109155A1 (en) 2008-05-30
IL183514A (en) 2015-11-30
ATE477254T1 (de) 2010-08-15
KR20120127754A (ko) 2012-11-23

Similar Documents

Publication Publication Date Title
EP1836201B2 (de) Pyrrolidine als inhibitoren von iap
US8063218B2 (en) Imidazopyridine inhibitors of IAP
US8247557B2 (en) IAP inhibitors
EP1778718B1 (de) Iap-inhibitoren
EP2240506B1 (de) Iap-hemmer
US20110218211A1 (en) Azaindole inhibitors of iap

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070716

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

17Q First examination report despatched

Effective date: 20080220

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1109155

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005022936

Country of ref document: DE

Date of ref document: 20100923

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Effective date: 20101215

REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1109155

Country of ref document: HK

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101213

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101211

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101111

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20101112

PLBI Opposition filed

Free format text: ORIGINAL CODE: 0009260

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

PLAX Notice of opposition and request to file observation + time limit sent

Free format text: ORIGINAL CODE: EPIDOSNOBS2

26 Opposition filed

Opponent name: NAEFE, JAN ROBERT

Effective date: 20110511

REG Reference to a national code

Ref country code: DE

Ref legal event code: R026

Ref document number: 602005022936

Country of ref document: DE

Effective date: 20110511

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20101231

PLAF Information modified related to communication of a notice of opposition and request to file observations + time limit

Free format text: ORIGINAL CODE: EPIDOSCOBS2

PLBB Reply of patent proprietor to notice(s) of opposition received

Free format text: ORIGINAL CODE: EPIDOSNOBS3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20110212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100811

APBM Appeal reference recorded

Free format text: ORIGINAL CODE: EPIDOSNREFNO

APBP Date of receipt of notice of appeal recorded

Free format text: ORIGINAL CODE: EPIDOSNNOA2O

APAH Appeal reference modified

Free format text: ORIGINAL CODE: EPIDOSCREFNO

APBU Appeal procedure closed

Free format text: ORIGINAL CODE: EPIDOSNNOA9O

PUAH Patent maintained in amended form

Free format text: ORIGINAL CODE: 0009272

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: PATENT MAINTAINED AS AMENDED

27A Patent maintained in amended form

Effective date: 20130904

AK Designated contracting states

Kind code of ref document: B2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK YU

REG Reference to a national code

Ref country code: HK

Ref legal event code: AM43

Ref document number: 1109155

Country of ref document: HK

Ref country code: CH

Ref legal event code: AELC

REG Reference to a national code

Ref country code: DE

Ref legal event code: R102

Ref document number: 602005022936

Country of ref document: DE

Effective date: 20130904

REG Reference to a national code

Ref country code: DK

Ref legal event code: T4

Effective date: 20131107

REG Reference to a national code

Ref country code: ES

Ref legal event code: DC2A

Ref document number: 2349110

Country of ref document: ES

Kind code of ref document: T5

Effective date: 20131127

REG Reference to a national code

Ref country code: SE

Ref legal event code: RPEO

REG Reference to a national code

Ref country code: NL

Ref legal event code: T3

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20130904

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20221214

Year of fee payment: 18

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 20231121

Year of fee payment: 19

Ref country code: LU

Payment date: 20231121

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20231124

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20231121

Year of fee payment: 19

Ref country code: IE

Payment date: 20231123

Year of fee payment: 19

Ref country code: FR

Payment date: 20231122

Year of fee payment: 19

Ref country code: DK

Payment date: 20231121

Year of fee payment: 19

Ref country code: DE

Payment date: 20231121

Year of fee payment: 19

Ref country code: AT

Payment date: 20231123

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 20231121

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20240102

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: CH

Payment date: 20240101

Year of fee payment: 19